Associated Papers
Frequencies of CYP2C9 polymorphisms in a Syrian cohort.
Aldiban W et al.
Bmc Genomics, 2025
Missense VKOR mutants exhibit severe warfarin resistance but lack VKCFD via shifting to an aberrantly reduced state.
Li S et al.
Blood Advances, 2023
The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data.
Zhou Y et al.
The Pharmacogenomics Journal, 2022
36068297 (PubMed )
Supplement: 41397_2022_288_MOESM4_ESM.xlsx › Sheet1
Pharmacogenetics in Jewish populations.
Yang Y et al.
Drug Metabolism and Drug Interactions, 2014
Novel associations of VKORC1 variants with higher acenocoumarol requirements.
Anton AI et al.
Plos One, 2013
VKORC1 mutations detected in patients resistant to vitamin K antagonists are not all associated with a resistant VKOR activity.
Hodroge A et al.
Journal of Thrombosis and Haemostasis : Jth, 2012
Pharmacogenetics in cardiovascular antithrombotic therapy.
Marín F et al.
Journal of the American College of Cardiology, 2009
CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.
Scott SA et al.
Pharmacogenomics, 2009
Multiple genetic alterations in vitamin K epoxide reductase complex subunit 1 gene (VKORC1) can explain the high dose requirement during oral anticoagulation in humans.
Bodin L et al.
Journal of Thrombosis and Haemostasis : Jth, 2008
Building individualized medicine: prevention of adverse reactions to warfarin therapy.
Krynetskiy E et al.
The Journal of Pharmacology and Experimental Therapeutics, 2007
Select a paper to view details